Mafalda Oliveira Archives

Patritumab deruxtecan reduces serious side effects in breast cancer patients compared to conventional chemotherapy while maintaining treatment efficacy

The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…

Next-generation SERD camizestrant significantly reduces risk of disease progression in patients with advanced ER+ HER2- breast cancer

• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…

Approved by EMA, novel oral AKT inhibitor in combination improves clinical outcomes and prolongs quality of life in patients with advanced HR+/HER2- breast cancer

Based on results from the CAPITello-291 phase III study, co-led by VHIO’s Mafalda Oliveira, Senior Medical Oncologist at Vall d’Hebron…

Novel chemotherapy-free strategy shows promise in patients with HER2-positive and hormone-receptor positive metastatic breast cancer (HER2+/HR+)

Results from an international Phase IIa study point to the promise of adding bispecific HER2-targeted antibody zanidatamab to the combination…

Novel AKT inhibitor combined with standard hormone therapy shows promise for patients with pre-treated metastatic HR+/ HER2- breast cancer

Approximately 70% of advanced breast cancers are hormone receptor-positive (HR+)/HER2-negative. Hormone therapies are widely used for the treatment of patients…

SOLTI-TOT-HER3 window of opportunity trial: final results show that lower dose patritumab deruxtecan is less toxic and does not compromise efficacy in the treatment of breast cancer

Presented at the 2023 ESMO Breast Cancer Annual Congress, 11-13 May in Berlin, final results of the SOLTI-TOT-HER3 window of…

Next-generation SERD camizestrant significantly improves progression-free survival vs. fulvestrant in advanced ER+ HER2- breast cancer

Presented today (1) at the 45th annual San Antonio Breast Cancer Symposium® (2022 SABCS®), results of the phase II SERENA-2…